Other exclusions include an eGFR of more than 25, a history of unstable or rapidly progressing kidney disease, severe gastroparesis or other gastric emptying conditions, pancreatitis, diabetic macular edema, and certain types of diabetic retinopathy
Final Thoughts: Staying Ahead of the Curve Deciding to use medical weight loss treatments is an investment in your longevity
Current Research Status: What Peer-Reviewed Studies Show The key evidence comes from a 2023 NEJM phase 2 trial (Jastreboff et al.)
Product Specifications Synonyms: LY3298176, P1206, tirzepatida, tirzepatidum CAS Number: 2023788-19-2 Molecular Formula: CHNO Molecular Weight: 4813.48 g/mol g/mol Peptide Sequence: Tyr-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-Aib-Leu-Asp-Lys-Ile-Ala-Gln-Lys(C20)-Ala-Phe-Val-Gln-Trp-Leu-Ile-Ala-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH Purity: 95% (verified by HPLC and mass spectrometry) Packaging Format: 40 mg lyophilized powder in a sealed research-grade vial Storage Conditions: Store 28 C (20 C long term)
Because this was apparent following acute and steady-state administration, differences in plasma half-lives alone do not explain this difference
Those with a BMI between 35 and 40 qualify if they have an obesity-related condition such as high blood pressure, sleep apnea, reflux, high cholesterol, or other related issues
